The data supports tirzepatide as a highly effective tool, perhaps one of the most effective pharmacological options currently available, but calling it a miracle oversimplifies the complexity of weight management and sets unrealistic expectations that could lead to frustration and treatment abandonment
26 Clinical trials show peak average weight loss occurring well beyond a year: around 68 weeks for Wegovy (~15% loss) 52 and 72 weeks for Zepbound (~21-22% loss at the highest dose)
The nurse will come to your location at the scheduled appointment time
The trial targeted people who are overweight or obese who have high cardiovascular risk but not diabetes
Although direct clinical evidence linking GIPR polymorphisms to tirzepatide response is currently lacking, existing studies suggest a mechanistic rationale in which rs2287019, rs10423928, and other GIPR variants could potentially influence tirzepatide efficacy by altering insulin secretion and glucose homeostasis [37,38]
That advantage owes nothing to the studys finding on survival but the two happen, for now, to point in the same direction
